1 序文
2 調査範囲と方法論
2.1 調査の目的
2.2 ステークホルダー
2.3 データソース
2.3.1 一次情報源
2.3.2 二次情報源
2.4 市場推定
2.4.1 ボトムアップアプローチ
2.4.2 トップダウンアプローチ
2.5 予測方法
3 エグゼクティブ・サマリー
4 はじめに
4.1 概要
4.2 主要業界動向
5 世界のジェネリック医薬品市場
5.1 市場概要
5.2 市場パフォーマンス
5.3 地域別市場構成
5.4 市場予測
6 がん用ジェネリック医薬品の世界市場
6.1 市場概要
6.2 市場動向
6.3 COVID-19の影響
6.4 主要なジェネリックがん治療薬
6.5 価格分析
6.6 市場予測
6.7 SWOT分析
6.7.1 概要
6.7.2 強み
6.7.3 弱点
6.7.4 機会
6.7.5 脅威
6.8 バリューチェーン分析
6.8.1 研究開発
6.8.2 製造
6.8.3 マーケティング
6.8.4 流通
6.9 ポーターのファイブフォース分析
6.9.1 概要
6.9.2 買い手の交渉力
6.9.3 供給者の交渉力
6.9.4 競争の程度
6.9.5 新規参入の脅威
6.9.6 代替品の脅威
6.9.7 ジェネリック医薬品業界における規制
6.10 主な市場促進要因と成功要因
7 世界のジェネリックがん治療薬市場主要地域の業績
7.1 北米
7.2 欧州
7.3 アジア太平洋
7.4 中東・アフリカ
7.5 ラテンアメリカ
8 世界のジェネリックがん治療薬市場競争環境
8.1 市場構造
8.2 主要プレイヤー別市場構成
8.3 主要プレイヤーのプロファイル
9 ジェネリックがん治療薬の製造プロセス
9.1 製品概要
9.2 詳細なプロセスフロー（錠剤）
9.3 詳細なプロセスフロー（注射剤）
9.4 関係する各種単位操作
9.5 マスバランスと原材料要件
10 プロジェクトの詳細、要件、および関連費用
10.1 土地要件と費用
10.2 建設要件と費用
10.3 工場機械
10.4 機械写真
10.5 原材料の要件と支出
10.6 包装の要件と支出
10.7 輸送要件および支出
10.8 ユーティリティの要件と支出
10.9 人員要件と支出
10.10 その他の設備投資
11 ローンと資金援助
12 プロジェクトの経済性
12.1 プロジェクトの資本コスト
12.2 技術経済パラメータ
12.3 サプライチェーンの各段階における製品価格とマージン
12.4 課税と減価償却
12.5 収入予測
12.6 支出予測
12.7 財務分析
12.8 利益分析
図1：世界：ジェネリック医薬品市場：主な推進要因と課題
図2：世界：ジェネリック医薬品市場：図2：世界のジェネリック医薬品市場：販売額推移（単位：億米ドル）、2019年〜2024年
図3：世界：ジェネリック医薬品市場予測：図3：ジェネリック医薬品の世界市場予測：売上金額推移（単位：億ドル）、2025年～2033年
図4：世界：ジェネリック医薬品市場：地域別構成比（単位：%）、2024年
図5：世界：ジェネリックがん治療薬産業概観
図6：世界：ジェネリックがん治療薬市場：売上金額推移（単位：億米ドル）、2019年～2024年
図7：世界：ジェネリックがん治療薬市場予測：売上金額推移（単位：億ドル）、2025年～2033年
図8：世界のジェネリックがん治療薬市場：地域別構成比（単位：%）、2024年
図9：世界：ジェネリックがん治療薬産業：SWOT分析
図10：世界：ジェネリックがん治療薬業界：バリューチェーン分析
図11: 世界のジェネリックがん治療薬産業：ポーターのファイブフォース分析
図12: 北米：北米：ジェネリックがん治療薬市場（単位：百万米ドル）、2019年、2025年、2033年
図13：アジア太平洋地域ジェネリックがん治療薬市場（単位：百万米ドル）、2019年、2025年、2033年
図14: 欧州：がん治療薬のジェネリック医薬品市場（単位：百万米ドル）、2019年、2025年、2033年
図15：ラテンアメリカ：がん治療薬のジェネリック医薬品市場（単位：百万米ドル）、2019年、2025年、2033年
図16：中東およびアフリカ：ジェネリックがん治療薬市場（単位：百万米ドル）、2019年、2025年、2033年
図17：ジェネリックがん治療薬業界：サプライチェーンの各段階における利益率
図18：ジェネリックがん治療薬の製造：製造コストの内訳
図19：ジェネリックがん治療薬製造工場：詳細なプロセスフロー
図 20: ジェネリックがん治療薬製造プロセス：原料の転換率
図 21: ジェネリック腫瘍薬製造プラント：工場レイアウト案
図 22: ジェネリック腫瘍薬製造プラント：資本コストの内訳
表一覧
表1：世界：ジェネリック医薬品市場：主要産業ハイライト、2024年および2033年
表2：世界：ジェネリック医薬品市場予測：地域別内訳、2025年〜2033年
表3：世界の腫瘍用ジェネリック医薬品市場：主要産業別ハイライト、2024年および2033年
表4：ジェネリックがん治療薬製造工場：土地と用地開発に関する費用（単位：米ドル）
表5：ジェネリック腫瘍薬製造プラント：土地・用地開発関連コスト（単位：米ドル土木工事関連コスト（単位：米ドル）
表6: ジェネリック腫瘍薬製造プラント：機械ユニット関連費用（単位：米ドル）
表7: ジェネリック腫瘍薬製造プラント：原材料所要量
表8: ジェネリック腫瘍薬製造プラント：給与賃金関連コスト（単位：米ドル）
表9: ジェネリック腫瘍薬製造工場：その他の設備投資に関する費用（単位：米ドル）
表10: 金融機関が提供する資金援助の詳細
表11：ジェネリック腫瘍薬製造工場：資本コスト（単位：米ドル）
表12：ジェネリック腫瘍薬製造プラント：技術経済パラメータ
表13: ジェネリック腫瘍薬製造プラント：課税と減価償却
表14: ジェネリック腫瘍薬製造プラント：収入予測（単位：米ドル）
表15: ジェネリック腫瘍薬製造プラント：支出予測（単位：米ドル）
表16: ジェネリック腫瘍薬製造プラント：法人税負担を考慮しないキャッシュフロー分析
表17: ジェネリックがん治療薬製造プラント：所得税負担を考慮したキャッシュフロー分析
表18: ジェネリック・オンコロジー医薬品製造工場：損益計算書
The global generic oncology drugs market size reached USD 30.7 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 46.8 Billion by 2033, exhibiting a growth rate (CAGR) of 4.8% during 2025-2033. The growing prevalence of cancer due to excessive smoking of tobacco products and consumption of alcohol, rising investments in research operations for developing novel drugs, and increasing implementation of stringent regulations for streamlining the drug production process are some of the major factors propelling the growth of the market.
Generic Oncology Drugs Market Analysis:
Market Growth and Size: The generic oncology drugs market is experiencing stable growth, driven by the increasing cancer prevalence and the growing demand for cost-effective treatment options.
Major Market Drivers: Key drivers include the rising cancer prevalence, patent expirations of branded oncology drugs, government initiatives to control healthcare costs, and advancements in pharmaceutical manufacturing technologies.
Technological Advancements: Continuous innovations are leading to enhanced quality control, streamlined manufacturing processes, and improved formulation and delivery systems for generic oncology drugs.
Industry Applications: Generic oncology drugs are primarily used in cancer treatment across various cancer types, making them a vital component of cancer care. They offer cost-effective alternatives to branded drugs, increasing patient accessibility.
Key Market Trends: Key trends include the growing adoption of biosimilars in oncology, personalized medicine approaches, and the influence of telemedicine and remote healthcare services on drug delivery. These trends reflect evolving patient needs and healthcare practices.
Geographical Trends: The North America region exhibits significant growth in the generic oncology drugs market due to the high cancer prevalence, stringent regulatory frameworks, and emphasis on cost containment. Asia Pacific is also witnessing significant developments on account of rising investments in medical research operations.
Competitive Landscape: The market features a competitive landscape with multiple pharmaceutical companies actively engaged in research and development (R&D) and manufacturing of generic oncology drugs. Strategic partnerships and acquisitions are common strategies to strengthen market positions.
Challenges and Opportunities: Challenges include navigating complex regulatory processes, ensuring product quality and safety, and addressing competition. However, these challenges also present opportunities for expanding product portfolios, meeting the demand for personalized cancer treatments, and entering emerging markets with unmet healthcare needs. Overall, the market presents significant growth potential for players who can navigate these challenges effectively.
Generic Oncology Drugs Market Trends:
Increasing Cases of Cancer
The increasing cases of cancer around the world represent one of the crucial factors impelling the growth of the market. This rise in cancer diagnoses is leading to a series of developments and transformations within the pharmaceutical industry, particularly in the domain of generic oncology drugs. These transformations, driven by the heightened cancer incidence, are multifaceted and have far-reaching implications that contribute to the accessibility and effectiveness of generic oncology drugs. With cancer emerging as a leading cause of morbidity and mortality, the availability of cost-effective and reliable treatment options is paramount. Generic oncology drugs, often more affordable than their branded counterparts, are ideally positioned to meet this demand and provide accessible solutions for patients across diverse socioeconomic backgrounds. Their affordability and accessibility make them indispensable tools in the fight against cancer, ensuring that patients receive timely and adequate care. This alleviation of healthcare system pressures enhances the overall efficiency and effectiveness of cancer treatment, ultimately benefiting patients.
Government Initiatives and Regulations
Government regulatory agencies oversee the approval and market entry of generic oncology drugs. They establish rigorous standards to evaluate the safety and efficacy of these medications before granting approval. These standards are critical in ensuring that generic drugs are reliable and effective alternatives to their branded counterparts. Government policies related to patent expiration and market exclusivity periods significantly impact the availability of generic oncology drugs. When patents for branded oncology drugs expire, regulatory agencies may grant approval for generic versions to enter the market. This process is guided by legal frameworks, which encourage competition and affordability in the pharmaceutical industry. Regulatory agencies oversee pharmacovigilance programs to monitor and assess the safety of generic oncology drugs once they are on the market. These agencies also enforce quality control standards to maintain the consistent quality and purity of medications, ensuring that patients receive safe and effective treatments. Moreover, governing agencies of various countries are providing incentives, such as research grants or tax benefits, to encourage pharmaceutical companies to invest in the development of generic oncology drugs.
Technological Advancements in Manufacturing
The rising advancements in the manufacturing of generic oncology drugs are supporting the market growth. Advanced manufacturing technologies, such as continuous manufacturing and real-time monitoring systems, are improving the quality control of generic oncology drugs. These systems enable pharmaceutical companies to maintain consistent product quality, reducing the risk of variations that can impact patient outcomes. This enhanced quality assurance instils confidence in the effectiveness of generic drugs. Automation and robotics are streamlining the manufacturing processes of generic oncology drugs. This increased efficiency results in higher production volumes, reduced production costs, and faster time-to-market for these medications. Technological advancements are also expanding the scalability of manufacturing operations. This is enabling generic oncology drug manufacturers to adjust production volumes more flexibly in response to market demand. Advances in drug formulation and delivery systems are facilitating the development of innovative generic oncology drug products. These technologies have the potential to enhance drug efficacy, reduce side effects, and improve patient compliance, all of which are critical factors in cancer treatment.
Patent Expirations and Cost-Effective Solutions
Patent expirations of several branded oncology drugs are opening opportunities for generic drug manufacturers. When patents for innovative cancer therapies expire, generic manufacturers can enter the market, offering lower-cost alternatives. This competition not only reduces the financial burden on patients but also contributes to healthcare cost containment. The availability of affordable generic oncology drugs ensures that more patients can access treatment, thereby fueling market growth.
Regulatory Support and Approval Pathways
Regulatory bodies are implementing expedited approval pathways for generic oncology drugs. Additionally, various government initiatives and policies encourage the development and manufacturing of generic oncology drugs. These regulatory supports create a favorable environment for generic drug manufacturers. Some regulatory agencies are also offering expedited pathways for the review and approval of generic oncology drugs, especially when there is a need for increased competition or when the drug in question addresses an unmet medical need. These pathways aim to streamline the approval process and facilitate timely market entry. Generic drug manufacturers may face patent challenges from innovator companies seeking to extend their exclusivity. Patent litigation and challenges play a role in the regulatory landscape, as the resolution of patent disputes can influence the timing of generic market entry.
Demand for Personalized Medicine
Advances in genomics and biomarker research are enabling a deeper understanding of the molecular mechanisms underlying cancer. This knowledge allows for the identification of specific genetic alterations and biomarkers associated with different types of cancer, paving the way for the development of targeted therapies. Personalized medicine in oncology often involves the use of targeted therapies designed to selectively inhibit cancer cell growth or survival based on specific molecular characteristics. As branded targeted therapies face patent expirations, generic equivalents are emerging to provide cost-effective alternatives, expanding access to personalized treatment options. The integration of companion diagnostics with personalized medicine is gaining prominence. Companion diagnostics help identify patients who are most likely to respond to a particular treatment, allowing healthcare providers to tailor therapeutic interventions based on the unique genetic profile of patients. Generic oncology drugs can be developed in tandem with companion diagnostics to enhance treatment efficacy.
Healthcare Cost Containment
Governments and healthcare providers are increasingly focusing on cost containment strategies. The use of generic oncology drugs helps in reducing overall healthcare costs, making cancer treatment more sustainable for healthcare systems. The increasing cost of healthcare, including oncology treatments, is becoming unsustainable for many healthcare systems. Moreover, as cancer prevalence rises and innovative therapies emerge, there is a growing need to find cost-effective solutions. Generic oncology drugs, often more affordable than their branded counterparts, play a crucial role in containing overall healthcare expenditures. Governments and healthcare payers are implementing policies promoting the use of generic drugs as a cost-saving measure. Generic substitution, where generic drugs replace branded ones, is actively encouraging to drive down the cost of cancer treatments. In the oncology sector, this can lead to significant savings, especially when dealing with high-cost biologics. The entry of generic oncology drugs creates pricing pressures on branded drugs. As generic alternatives become available, the competition often results in reduced prices for both generic and branded medications. This not only benefits patients but also supports healthcare cost containment initiatives.
Rising Acceptance of Generics
The rising acceptance of generics is supporting the growth of the market. Patients and healthcare systems alike benefit from the economic advantages offered by generic drugs, making essential medications more affordable. Clinical studies and real-world evidence support the notion that generic drugs perform comparably to brand-name drugs. As more evidence accumulates, healthcare professionals and patients become increasingly confident in the effectiveness of generic medications. The availability of generic versions is expanding across various therapeutic areas, ranging from chronic conditions like cardiovascular diseases and diabetes to acute conditions and infectious diseases. A broader generic drug portfolio contributes to increased acceptance as it covers a wide range of medical needs. Apart from this, efforts to enhance health literacy and educate patients about generic medications are increasing acceptance of generics. When patients understand that generics offer the same quality and efficacy as brand-name drugs, they are more likely to accept them as viable treatment options. Furthermore, the emergence of biosimilars, which are highly similar versions of biologic drugs, is receiving regulatory support in various regions. This support boosts confidence in the safety and efficacy of biosimilars, contributing to their acceptance as alternatives to expensive biologics.
Market Consolidation and Strategic Collaborations
Mergers and acquisitions are becoming prominent strategies for companies seeking to consolidate their positions in the generic oncology drugs market. Large pharmaceutical companies often acquire smaller players to gain access to their product portfolios, manufacturing capabilities, or research pipelines. This consolidation enhances operational efficiency and strengthens the overall competitiveness of the acquiring entity. Collaborations and partnerships allow companies to pool resources and expertise, accelerating the research and development (R&D) of generic oncology drugs. By combining knowledge and leveraging strengths, companies can bring new and improved generic formulations to market more efficiently. This is crucial in a sector where timely introduction of cost-effective alternatives is essential.
Generic Oncology Drugs Industry Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global and regional levels for 2025-2033.
Breakup by Region:
North America
Europe
Asia Pacific
Middle East and Africa
Latin America
North America leads the market, accounting for the largest generic oncology drugs market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. According to the report, North America accounted for the largest market share.
The North America generic oncology drug market is largely driven by the rising prevalence of cancer among the masses due to excessive consumption of alcohol and smoking tobacco products. Governing bodies and healthcare providers in the region are increasingly focused on containing healthcare costs. Generic oncology drugs, known for their cost-effectiveness, align with this goal and are preferred options in various healthcare systems. Stringent regulatory frameworks are governing and streamlining the approval of generic drugs. These regulations ensure the safety, efficacy, and quality of generic oncology drugs, instilling confidence among healthcare professionals and patients. Additionally, technological advancements in pharmaceutical manufacturing, such as continuous manufacturing and automation, are improving the efficiency and cost-effectiveness of producing generic oncology drugs.
Asia Pacific stands as another key region in the market, driven by the increasing investments to improve healthcare infrastructure, increase access to essential medicines, and control healthcare costs. The promotion of generic medications, including oncology drugs, is often a key component of these initiatives to make cancer treatment more affordable. The overall increase in healthcare expenditure in the Asia-Pacific region is leading to a greater emphasis on cost containment. Generic oncology drugs, being more affordable than their branded counterparts, are integral to managing the economic impact of cancer care.
Leading Key Players in the Generic Oncology Drugs Industry:
Key players in the generic oncology drugs market are actively engaged in various strategic initiatives to maintain and expand their market presence. These initiatives include the development and launch of new generic oncology drugs, often following the expiration of patents for branded medications. Additionally, top companies are investing in research and development (R&D) to enhance the quality and efficacy of their generic oncology drug offerings. They are also focusing on cost-efficient manufacturing processes, leveraging technological advancements to improve production efficiency. Marketing efforts emphasize the affordability and accessibility of their products to both patients and healthcare systems. Furthermore, strategic partnerships, collaborations, and acquisitions are becoming prevalent as companies seek to strengthen their portfolios and global reach in this competitive market. Leading companies are actively involving in developing and commercializing generic versions of various oncology medications. They are also prioritizing on biosimilars, including biosimilar versions of oncology drugs and involving in the development and commercialization of cost-effective alternatives to branded oncology biologics.
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided.
Key Questions Answered in This Report
1. What is the market size of the generic oncology drugs market?
2. What is the expected growth rate of the global generic oncology drugs market during 2025-2033?
3. What has been the impact of COVID-19 on the global generic oncology drugs market?
4. What are the key factors driving the global generic oncology drugs market?
5. What are the key regions in the global generic oncology drugs market?
6. What are the trends of the generic oncology drugs market?
7. What are the ethical issues in the development of generic oncology drugs?
